Tempest Therpeutics Inc (TPST) News

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a...

Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

BRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a...

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

BRISBANE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a...

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a...

Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

BRISBANE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a...

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Broad agreement on pivotal Phase 3 study plan, including use of current amezalpat dose and scheduleOverall...

Form 144 - Report of proposed sale of securities

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 144 - Report of proposed sale of securities

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

 Unveiled new positive survival data for amezalpat (TPST-1120) in randomized first-line hepatocellular...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form S-3 - Registration statement under Securities Act of 1933

Form 4 - Statement of changes in beneficial ownership of securities

Form 424B5 - Prospectus [Rule 424(b)(5)]